Unaudited Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024
Cash flows from operating activities
Net loss	$ (357,141)	$ (234,588)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense	56,542	53,504
Amortization of operating lease right-of-use assets	2,199	1,947
Non-cash interest expense	2,825	2,030
Loss (gain) on digital assets, net	383	0
Loss (gain) on disposal of property and equipment	1,715	2,511
Asset impairment	138,483	7,673
Stock-based compensation	2,492	2,252
Reserve on inventory	14,385	0
H.S.L. SRL. settlement adjustment	(295)	0
Settlement on accrued research and development expenses	0	(14,935)
Change in fair value of notes payable, warrant liabilities, and derivative liabilities	(36,721)	(28,927)
Change in fair value of related party notes payable, warrant liabilities, and derivative liabilities	3,283	(315)
Loss (gain) on foreign exchange	0	(40)
250000	250	366
Changes in operating assets and liabilities
Accounts receivables	(589)	0
Inventory	1,468	6,949
Loss (gain) on foreign exchange	2,582	1,157
Accounts payable	(10,838)	(1,736)
Operating lease liabilities	(2,684)	0
Financing lease liabilities	0	1,976
Other current and non-current assets	(4,392)	(2,134)
Net cash used in operating activities	(79,171)	(51,796)
Cash flows from investing activities
Investment in Qualigen Therapeutics, Inc., net of cash acquired	8,777	0
Proceeds from sale of equipment	0	87
Purchase of digital assets	(10,500)	0
Sale of digital assets	8,525	0
Payments for property and equipment	(6,525)	(659)
Net cash provided by (used in) investing activities	277	(572)
Cash flows from financing activities
Payments of notes payable and other financing obligations	(4,482)	(101)
Proceeds from other financial obligations	4,802	0
Proceeds from exercise of warrants	1,441	0
Net cash provided by financing activities	135,783	55,685
Effect of exchange rate changes on cash and restricted cash	(1,126)	7
Net (decrease) increase in cash and restricted cash	55,763	3,324
Cash and restricted cash, beginning of period	7,174	4,025
Cash and restricted cash, end of period	62,937	7,349
Cash and restricted cash
Cash	62,909	7,269
Restricted cash	28	80
Cash, cash equivalents, restricted cash, and restricted cash equivalents	62,937	7,349
Supplemental disclosure of cash flow information
Cash paid for interest	4,194	2,988
Cash paid for taxes	0	0
Supplemental disclosure of noncash investing and financing activities
Conversion of notes payable and accrued interest into Class A Common Stock	57,341	44,891
Issuance of warrants and related party warrants with the SPA Portfolio Notes	48,110	17,914
Settlement of vendor liability in Class A Common Stock	2,245	0
Non-Cash Warrant Exercise Activity and FV Reclassifications to Equity	12,649	0
Additions of property and equipment included in accounts payable and accrued expenses	42,717	45,455
RSU tax withholdings	0	10
Purchase of Class A Common Stock under the Salary Deduction and Stock Purchase Agreements	0	36
Recognition of right-of use assets and liabilities for new leases and lease modifications	6,260	0
Supplemental disclosure of noncash operating activities
Settlement of Palantir dispute with issuance of Class A Common Stock	0	2,400
Nonrelated Party
Adjustments to reconcile net loss to net cash used in operating activities:
Loss on settlement of notes payable	84,895	117,509
Changes in operating assets and liabilities
Accrued expenses and other current liabilities	17,644	7,554
Cash flows from financing activities
Payments of notes payable issuance costs	(2,540)	(1,310)
Proceeds from notes payable, net of original issuance discount	132,391	54,021
Related Party
Adjustments to reconcile net loss to net cash used in operating activities:
Loss on settlement of notes payable	3,040	14,295
Changes in operating assets and liabilities
Accrued expenses and other current liabilities	1,303	3,612
Related party accrued interest expense	0	7,544
Cash flows from financing activities
Payments of notes payable issuance costs	(560)	0
Proceeds from notes payable, net of original issuance discount	$ 4,731	$ 3,075